38.12
Harmony Biosciences Holdings Inc stock is traded at $38.12, with a volume of 388.56K.
It is down -0.99% in the last 24 hours and up +9.51% over the past month.
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
See More
Previous Close:
$38.50
Open:
$38.22
24h Volume:
388.56K
Relative Volume:
0.47
Market Cap:
$2.22B
Revenue:
$899.11M
Net Income/Loss:
$145.62M
P/E Ratio:
15.35
EPS:
2.4829
Net Cash Flow:
$322.54M
1W Performance:
-0.76%
1M Performance:
+9.51%
6M Performance:
+5.86%
1Y Performance:
+4.41%
Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile
Name
Harmony Biosciences Holdings Inc
Sector
Industry
Phone
(484) 539-9800
Address
630 W GERMANTOWN PIKE, PLYMOUTH MEETING
Compare HRMY vs VRTX, REGN, ARGX, RVMD, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
|
HRMY
Harmony Biosciences Holdings Inc
|
38.12 | 2.32B | 899.11M | 145.62M | 322.54M | 2.4829 |
|
VRTX
Vertex Pharmaceuticals Inc
|
505.75 | 133.25B | 12.34B | 4.34B | 3.71B | 16.87 |
|
REGN
Regeneron Pharmaceuticals Inc
|
803.48 | 82.16B | 14.92B | 4.42B | 3.79B | 41.04 |
|
ARGX
Argen X Se Adr
|
851.29 | 54.80B | 4.16B | 1.29B | 734.26M | 19.58 |
|
RVMD
Revolution Medicines Inc
|
203.71 | 43.99B | 742.00K | -1.37B | -1.07B | -7.0731 |
|
ONC
Beone Medicines Ltd Adr
|
347.48 | 40.62B | 5.76B | 514.49M | 1.10B | 4.4813 |
Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-23-26 | Downgrade | Deutsche Bank | Buy → Hold |
| Feb-23-26 | Downgrade | Truist | Buy → Hold |
| Feb-11-26 | Resumed | UBS | Neutral |
| Jul-21-25 | Initiated | Truist | Buy |
| Jul-10-25 | Resumed | Goldman | Neutral |
| Jun-02-25 | Resumed | Oppenheimer | Outperform |
| Feb-11-25 | Initiated | Deutsche Bank | Buy |
| Dec-17-24 | Initiated | H.C. Wainwright | Buy |
| Oct-10-24 | Resumed | Raymond James | Outperform |
| Sep-10-24 | Initiated | UBS | Buy |
| Jun-21-24 | Initiated | Citigroup | Buy |
| Jan-02-24 | Downgrade | BofA Securities | Neutral → Underperform |
| Sep-25-23 | Downgrade | Goldman | Neutral → Sell |
| Sep-07-23 | Initiated | Berenberg | Buy |
| Apr-20-23 | Initiated | BofA Securities | Neutral |
| Oct-14-22 | Upgrade | Janney | Neutral → Buy |
| Oct-14-22 | Upgrade | Jefferies | Hold → Buy |
| Aug-03-22 | Downgrade | Jefferies | Buy → Hold |
| Jul-13-22 | Downgrade | Goldman | Buy → Neutral |
| Jul-07-22 | Initiated | Mizuho | Buy |
| Apr-14-22 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-01-21 | Initiated | Oppenheimer | Outperform |
| Nov-04-21 | Initiated | Raymond James | Outperform |
| Sep-23-21 | Initiated | Needham | Buy |
| Mar-29-21 | Upgrade | Goldman | Neutral → Buy |
| Sep-14-20 | Initiated | Goldman | Neutral |
| Sep-14-20 | Initiated | Jefferies | Buy |
| Sep-14-20 | Initiated | Piper Sandler | Overweight |
View All
Harmony Biosciences Holdings Inc Stock (HRMY) Latest News
Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline - MarketBeat
HRMY: Record WAKIX sales drive CNS pipeline progress, with BP-205 and new pitolisant forms advancing - TradingView
Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail
Zacks Research Downgrades Harmony Biosciences (NASDAQ:HRMY) to Hold - MarketBeat
Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance
Hennion & Walsh Asset Management Inc. Decreases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings, Inc. $HRMY Shares Sold by Janus Henderson Group PLC - MarketBeat
(HRMY) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Why Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Surge And Pipeline Progress - Sahm
Harmony Biosciences (NASDAQ:HRMY) Upgraded by Wall Street Zen to "Buy" Rating - MarketBeat
Harmony Biosciences (HRMY) Is Up 9.0% After Q2 Earnings Jump And Pipeline ProgressWhat's Changed - Yahoo Finance
Harmony Biosciences (NASDAQ: HRMY) holder to sell 700,883 shares - Stock Titan
Harmony Biosciences Holdings, Inc. Just Recorded A 34% EPS Beat: Here's What Analysts Are Forecasting Next - Moomoo
First Trust Advisors LP Sells 50,805 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Holdings Inc (HRMY) Stock News Today - tradingkey.com
Harmony Biosciences Holdings Inc (HRMY) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Harmony Biosciences Holdings (HRMY) Could Be 19% Undervalued On Strong Q2 Earnings - Sahm
Harmony Biosciences to Participate in Piper Sandler Virtual CNS Symposium - The Manila Times
Harmony Biosciences management plans Aug. 13 fireside chat webcast - Stock Titan
Harmony Biosciences: Management Raised Its Game, But The Stock Has Already Rerated (HRMY) - Seeking Alpha
HRMY Q2 Earnings Beat Estimates on Strong Wakix Sales, Stock Up - Yahoo Finance
Analysts Are Bullish on These Healthcare Stocks: Harmony Biosciences Holdings (HRMY), Beam Therapeutics (BEAM) - The Globe and Mail
Here is Why Growth Investors Should Buy Harmony Biosciences (HRMY) Now - Yahoo Finance
Deutsche Bank Adjusts Harmony Biosciences Price Target to $39 From $36, Maintains Hold Rating - marketscreener.com
Harmony Biosciences Says New Data Supports Neurology Pipeline - benzinga.com
Harmony Biosciences Holdings, Inc. $HRMY Stock Holdings Lifted by Pacer Advisors Inc. - MarketBeat
Harmony Biosciences Q2 2026 slides: record WAKIX quarter, BP-205 data - Investing.com
Sei Investments Co. Has $5.44 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat
Harmony Biosciences Q2 2026 earnings: WAKIX revenue rises 30% - TradingKey
Harmony Biosciences Holdings Inc (HRMY) (Q2 2026) Earnings Call - GuruFocus
Harmony Biosciences Holdings, Inc. Stock 12‑Month Price Target Cut to $44.7, Implies 26% Upside - TradingView
Harmony Biosciences Holdings, Inc. Q2 2026 Earnings Call Summary - Yahoo Finance
Harmony Biosciences Holdings, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:HRMY) 2026-08-04 - Seeking Alpha
Harmony Biosciences Holdings Inc (HRMY) (Q2 2026) Earnings Call Highlights: Record Revenue and ... - Yahoo Finance UK
Harmony Biosciences Holdings Surges 11.0% Amid Sector-Wide Rally - AlphaStreet
Harmony Biosciences Holdings Inc. (HRMY) PT Lowered to $70 at Oppenheimer - StreetInsider
Oppenheimer lowers Harmony Biosciences stock price target on model updates - Investing.com
Needham & Company LLC Forecasts Strong Price Appreciation for Harmony Biosciences (NASDAQ:HRMY) Stock - MarketBeat
Is Harmony Biosciences (HRMY) Undervalued After Q2 Earnings? EPS - GuruFocus
Harmony Biosciences Q2 Earnings Call Highlights - MarketBeat
Harmony Biosciences (NASDAQ:HRMY) Stock Price Up 11.4% Following Strong Earnings - MarketBeat
Harmony Biosciences Shares Rise After Q2 Earnings, Product Revenue Increase - marketscreener.com
Harmony Biosciences Holdings Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Harmony Biosciences Holdings, Inc. (HRMY) Beats Q2 Earnings and Revenue Estimates - Yahoo Finance
Harmony Biosciences 2Q 2026: Revenue $261.28M, EPS $1.28— 10-Q Summary - tradingview.com
Harmony Biosciences (NASDAQ: HRMY) lifts Q2 profit as WAKIX sales grow - Stock Titan
(HRMY) Harmony Biosciences Expects 2026 Wakix Net Revenue Range $1.0B to $1.04B - marketscreener.com
Earnings Flash (HRMY) Harmony Biosciences Posts Q2 EPS $1.28, vs. FactSet Est of $0.96 - marketscreener.com
Harmony Biosciences Announces Record Q2 2026 Revenue and Shares Initial Clinical Data for Its Orexin-2 Agonist BP-205 Reinforcing Potential Best-in-Class Profile - The Manila Times
Harmony Biosciences Announces Record Q2 2026 Revenue and - GlobeNewswire
Harmony Biosciences Holdings, Inc. (HRMY): Investor Outlook with a Promising 27.81% Potential Upside - DirectorsTalk Interviews
Harmony Biosciences Holdings Inc Stock (HRMY) Financials Data
Revenue
Net Income
Cash Flow
EPS
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):